Fig. 2.

Secondary endpoints. (a) Median (interquartile range) serum testosterone (ng/mL) and (b) median (interquartile range) percentage change in serum prostate-specific antigen (PSA; ng/mL), over time in patients receiving degarelix 240/80 mg in CS42 and CS21 (240/80 mg, non-Asian patients; full analysis set).